XTL Biopharmaceuticals Ltd.
XTLB · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Market Cap | $14 | $13 | $12 | $16 |
| - Cash | $0 | $1 | $1 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $13 | $12 | $11 | $15 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 78.4% | – | – | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -14.9% | 100% | – | – |
| EBITDA | -$0 | -$0 | -$1 | $0 |
| % Margin | -148.5% | -96.3% | – | – |
| Net Income | -$0 | -$1 | -$1 | $0 |
| % Margin | -88.2% | -341.4% | – | – |
| EPS Diluted | -0.04 | -0.1 | -0.13 | 0.09 |
| % Growth | 60% | 23.1% | -244.4% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |